Zealand Pharma A/s
COPENHAGEN, Denmark and INGELHEIM, Germany, June 16, 2011 -
- Boehringer
Ingelheim Obtains Global Rights to
glucagon/GLP-1 Dual Agonists, including
ZP2929, Zealand Pharma's
Lead Drug Candidate in This
Class
- Zealand Pharma is
Eligibleto Receive Total
Projected Milestone Payments
of up to €376 million for ZP2929
Today, Zealand Pharma (NASDAQ OMX: ZEAL), a Copenhagen based
biopharmaceutical company, and Boehringer Ingelheim, one of the
world's leading pharmaceutical companies, jointly announced an
exclusive global licence and collaboration agreement for
dual-acting glucagon and GLP-1 receptor agonists for the treatment
of patients with Type-2 diabetes and patients with obesity.
COPENHAGEN, Denmark, February 2, 2011 - Zealand Pharma A/S (NASDAQ OMX: ZEAL), a biopharmaceutical
company dedicated to the discovery and development of innovative peptide
drugs, is pleased to announce that its partner, sanofi-aventis, today
announced that the GetGoal-X Phase III study of lixisenatide, a once-daily
GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary
endpoint of non-inferiority in HbA1c reduction from baseline, compared with
exenatide twice-daily.
COPENHAGEN, December 9, 2010 - Zealand Pharma A/S (NASDAQ OMX: ZEAL) ("Zealand Pharma" or
"the Company"), a biopharmaceutical company dedicated to the discovery and
development of innovative peptide drugs that recently listed on NASDAQ OMX,
today announces the receipt of a EUR 500,000 (DKK 3.73 million*) milestone
payment as part of its license agreement with Helsinn Healthcare for the
development of ZP1846 for the treatment of chemotherapy-induced diarrhoea.
COPENHAGEN, September 30, 2010 - Zealand Pharma A/S, the biopharmaceutical company dedicated to
the discovery and development of innovative peptide-based drugs, is pleased
to note that its partner, sanofi-aventis, has today announced positive
top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the
efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist
discovered by Zealand Pharma, in combination with basal insulin.
